United Health Products, Inc. (OTC: UEEC) (“UHP” or the “Company”), today announced that it has filed a non-provisional patent application with the U.S. Patent & Trademark Office for the hydrocolloid (gel) format of its HemoStyp oxidized regenerated cellulose product, and has also filed a separate application under the Patent Cooperation Treaty with the World Intellectual Property Organization. The Patent Cooperation Treaty (PCT) is an international patent law treaty which provides a unified procedure for filing of a patent application in the majority of foreign countries. The Company previously filed a provisional patent application for the hydrocolloid technology in July 2019.
This latest patent application relates to methods of forming and using a hemostatic material and, more specifically, to methods of forming and using a hemostatic gel or foam material to control bleeding and oozing from a variety of wounds. The hemostatic hydrocolloid may be used both outside and inside the body and can be quickly absorbed by the human body when used internally. The coagulation properties of the hemostatic hydrocolloid may accelerate hemostasis. The hemostatic hydrocolloid can be fabricated in various forms to best suit the active bleeding situation, whether from an artery or vein, from internal bleeding during laparoscopic procedures, or on surfaces of bone tissue during orthopedic procedures.
About United Health Products
United Health Products develops technology; and manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The Company’s product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005373/en/
Copyright Business Wire 2020